Valiant Laboratories has demonstrated high ROCE, positive operating cash flows, strong balance sheet, pursued growth opportunities and better managed unanticipated cash flow variations, which will drive the company's performance going ahead, said StoxBox in his IPO note. The issue is fairly valued compared to its peers," it added with a 'subscribe' rating for the issue.Its financial performance has been improving, and it has the benefit of experienced promoters, but manufactures a single-product. It is dependent on a limited number of suppliers and customers. There is intense competition with high regulations. The issue is fairly priced, but considering other risks and current market volatility, we will avoid this IPO," said Swastika Investmart.Read more:
